Parabilis director granted 20,215 stock options

Parabilis Medicines, Inc. director Alexis Borisy received a grant of stock options covering 20,215 shares of common stock.

Rhea-AI Filing Summary

Parabilis Medicines, Inc. director Alexis Borisy received a grant of stock options covering 20,215 shares of common stock. The options have an exercise price of $20.00 per share and expire on June 8, 2036.

These options vest and become exercisable in full on the earlier of June 9, 2027 or the date of the company’s next annual meeting of stockholders, subject to Borisy’s continued service. Following this grant, Borisy holds 20,215 stock options directly, according to the filing.

Insights

Equity Compensation Analyst

Routine director option grant with long-dated upside exposure.

Director Alexis Borisy received 20,215 stock options with a $20.00 exercise price, expiring on June 8, 2036. The grant appears to be compensation-related rather than an open-market purchase or sale, so it carries limited direct trading signal.

The options vest fully on the earlier of June 9, 2027 or the next annual stockholder meeting, contingent on continued board service. This structure encourages longer-term alignment with shareholders, but the economic impact depends on Parabilis Medicines’ share price relative to the $20.00 strike over time.

Insider Trade Summary

Grant/Award: 20,215 shares

Grant/Award 1 txn

Insider Borisy Alexis

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	20,215	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 20,215 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 9, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

Key Figures

Options granted: 20,215 options Exercise price: $20.00 per share Expiration date: June 8, 2036 +3 more

6 metrics

Options granted 20,215 options Stock Option (Right to Buy) granted to director

Exercise price $20.00 per share Conversion or exercise price of options

Expiration date June 8, 2036 Option expiration date

Underlying shares 20,215 shares Common stock underlying the options

Holdings after grant 20,215 options Total derivative holdings following transaction

Vesting trigger date June 9, 2027 Latest possible full-vesting date, subject to service

Key Terms

Stock Option (Right to Buy), exercise price, vesting, annual meeting of stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 20.0000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The shares underlying this option shall vest and become exercisable in full"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders financial

"the date of the Issuer's next annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Parabilis Medicines (PBLS) director Alexis Borisy report on this Form 4?

Alexis Borisy reported receiving a grant of 20,215 stock options for Parabilis Medicines common stock. These options serve as equity compensation, giving him the right to buy shares at a fixed exercise price if the company’s share price later exceeds that level.

What are the key terms of Alexis Borisy’s Parabilis Medicines stock option grant?

The grant covers 20,215 stock options with an exercise price of $20.00 per share and an expiration date of June 8, 2036. These terms define the cost to exercise the options and the final date by which they must be exercised.

When do Alexis Borisy’s Parabilis Medicines (PBLS) options vest and become exercisable?

The options vest and become exercisable in full on the earlier of June 9, 2027 or the date of Parabilis Medicines’ next annual meeting of stockholders. Vesting is conditioned on Borisy’s continued service as a director through the applicable vesting date.

How many Parabilis Medicines options does Alexis Borisy hold after this Form 4 transaction?

After the reported transaction, Alexis Borisy holds 20,215 Parabilis Medicines stock options directly. This figure represents his position in the granted options following the award and provides context for the scale of his option-based exposure to the company’s equity.

Is this Parabilis Medicines (PBLS) Form 4 an open-market stock purchase or sale?

No, this Form 4 reflects a compensation-related grant of stock options coded as an acquisition (A), not an open-market buy or sell. The options give future purchase rights at $20.00 per share rather than recording an immediate cash transaction in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/11/2026 - 04:53 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Borisy Alexis

(Last) (First) (Middle)

C/O PARABILIS MEDICINES, INC.

30 ACORN PARK DRIVE, 6TH FLOOR

(Street)

CAMBRIDGE MASSACHUSETTS 02140

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Parabilis Medicines, Inc. [ PBLS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$20	06/09/2026		A		20,215		(1)	06/08/2036	Common Stock	20,215	$0	20,215	D

Explanation of Responses:

1. The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 9, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

	/s/ Teresa Jurgensen, Attorney-in-Fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)